The goal of this study was to test the hypothesis that the combined treatment using the EpCAM-targeting Ec1–LoPE toxin and the HER3-targeting monoclonal antibody MM-121 would increase the efficacy of experimental therapy in a pancreatic cancer model. This evidence concerns the gene EPCAM and familial pancreatic carcinoma.